"Liposarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
| Descriptor ID |
D008080
|
| MeSH Number(s) |
C04.557.450.550.420 C04.557.450.795.465
|
| Concept/Terms |
Liposarcoma, Dedifferentiated- Liposarcoma, Dedifferentiated
- Dedifferentiated Liposarcoma
- Dedifferentiated Liposarcomas
- Liposarcomas, Dedifferentiated
Liposarcoma, Pleomorphic- Liposarcoma, Pleomorphic
- Liposarcomas, Pleomorphic
- Pleomorphic Liposarcoma
- Pleomorphic Liposarcomas
|
Below are MeSH descriptors whose meaning is more general than "Liposarcoma".
Below are MeSH descriptors whose meaning is more specific than "Liposarcoma".
This graph shows the total number of publications written about "Liposarcoma" by people in this website by year, and whether "Liposarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 5 | 1 | 6 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 2 | 5 |
| 2014 | 5 | 1 | 6 |
| 2015 | 7 | 1 | 8 |
| 2016 | 3 | 0 | 3 |
| 2017 | 6 | 0 | 6 |
| 2018 | 6 | 0 | 6 |
| 2019 | 4 | 1 | 5 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 4 | 0 | 4 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liposarcoma" by people in Profiles.
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024 Jan; 122:102668.
-
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol. 2023 03 20; 41(9):1714-1724.
-
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
-
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov; 29(12):7335-7348.
-
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.
-
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
-
Pediatric liposarcoma: A case series and literature review. Pediatr Blood Cancer. 2021 12; 68(12):e29327.
-
A massive liposarcoma of the orbit. Orbit. 2023 10; 42(5):569-570.
-
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.
-
ASO Author Reflections: Surveillance After Resection of Retroperitoneal Well-Differentiated Liposarcoma: A Balancing Act Between Earlier Recurrence Detection, Patient Anxiety, and Health Care Resource Expenditure. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):748-749.